AGM Recollections

Memorable moments

1. Noxopharm and Nyrada now have employees who have taken drugs through to commercialisation.
2. Strategic and commercial master plans are being prepared, together with contingency plans, so that the company has ticked all boxes by the time Marketing Approval is granted
3. Nyrada is focussed on non-oncology matters, but some discoveries such as the anti-inflammatory IRAK4 inhibitor announced in September also have anti-cancer potential.
4. An independent expert will advise whether Nyrada should be re-merged into Noxopharm.
5. Chief Medical Officer, Greg van Wyk, looks to be a great acquisition
6. Multi-national Phase 2 Sarcoma trial to commence H1 2019. Rare cancer trials offer Fast Track Approval and Orphan Drug Status and approval based on smaller patient numbers
7. DARRT registration trial for prostate cancer to commence H2 2019
8. Professor Lenzo’s presentation can be found in lower half of https://www.noxopharm.com/site/PDF/1761_3/NOX2018AGMPresentations (about page 34).
9. Radiotherapy looks to be the next big step in cancer treatment.
10. Intravenous radiotherapy such as LuPSMA is effective for about 40% of patients, but has scope for improvement.
11. Novartis has spent over $6 billion acquiring companies in this field.
12. The decision to double numbers in the LuPIN trial at St Vincent’s (at considerable expense to Noxopharm) indicates that Veyonda significantly improves the performance of LuPSMA.
13. More DARRT-1 results should be released in December. Patients have a life expectancy of about 6 months.
14. Veyonda has the potential to be used as a radio-enhancer each time radiotherapy is used, including with early-stage cancer.
15. Potential income is $42 billion per year at $10,000 per course. The Directors liked those numbers.